Correlation between (Procalcitonin, CRP and interleukin-6) with cystatin C in type-2 diabetes mellitus patients

Main Article Content

Nesreen Ahmed Nasser
Anas H. Sadek
Zainab Sadeq Yuosif
Rayah Sulaiman Baban


Type II diabetes, cystatin C, Procalcitonin, interleukin-6, cystatin C


All nucleated cells consistently synthesize and secrete cystatin C, a basic protein that is not glycosylated. Because it is less influenced by outside variables including gender, race, and muscle mass, cystatin C is a more trustworthy measure than blood creatinine. Serum cystatin C levels in type 2 diabetes mellitus are not well understood in individuals with obesity, nevertheless. A low-molecular weight protein called cystatin C that is readily filtered by the kidneys has just come to light as a potential biomarker that may be utilized to identify early renal failure in people with type 1 or type 2 diabetes. Additionally, it has been demonstrated that cystatin C can be used to identify cardiovascular disease in diabetics, and it may possibly be connected to the occurrence of type ll diabetes in obese individuals. This study aimed correlation cystatin C (Cys C) levels in type ll diabetes and Procalcitonin , CRP and interleukin-6 .inflammatory marker
Material and methods: the blood samples of Type II diabetes mellitus (30 cases) and control (30 normal) groups were collected in private laboratory through the study dated between February 2022 and june 2022. HbA1c test was done immediately then the blood sample was centrifuged. Serum divided into two part. The first part was used for the following test : random blood sugar, total protein, albumin, GPT, GOT, ALP. The other was refrigerated for Procalcitonin , CRP, interleukin-6 and cystatin C tests by using enzyme-linked immunosorbent assay (ELISA).
Results: The mean cystatin-c levels were increased in Type II diabetes patients significantly (P≤ 0.0001) compared with healthy groups (2.55±1.12 pg/ml, 0.55±0.21pg/ml ) respectively. Also, CRP ,IL-6 and procalcitonin levels were bigger in Type II diabetes patients significantly (P > 0.0001) in Type 2 diabetes linked with healthy groups (30.45±16.4 ng/ml, 2.19±1.27 ng/ml , 16.19±4.32 ng/ml 6.06±3.10 and 4.92±4.00 , 0.315± 0.22 ) respectively.
Conclusions: According to our research, individuals with Type II diabetes have circulating Cys C levels that are higher than those of healthy individuals. To determine the cause of abnormal Cys C concentrations in Type II diabetes, more research is still required.

Abstract 254 | PDF Downloads 160


1. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019. Results. Institute for Health Metrics and Evaluation. 2020
2. Eschwege E: The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications. Diabetes Metab. 2003, 29 (4 Pt 2): 6S19-6S27.
3. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2011;29:116–122
4. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98–107
5. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acutephase reactants and interleukin-6 with metabolic syndrome-X. Diabetologia. 1997;40(11):1286-92.
6. Wannamethee SG, Lowe GDO, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007;30:1200–1205
7. Rehman K, Akash MSH, Liaqat A, Kamal S, Qadir MI, Rasul A. Role of Interleukin-6 in Development of Insulin Resistance and Type 2 Diabetes Mellitus. Crit Rev Eukaryot Gene Expr. 2017;27(3):229-236. doi: 10.1615/CritRevEukaryotGeneExpr.2017019712. PMID: 29199608. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature 2017;542:177–85.
8. Kaptoge S, Seshasai SRK, Gao P, Freitag DF, Butterworth AS, Borglykke A, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 2014;35:578–89.
9. Wang X, Sun Y, Shao X. Predictive value of procalcitonin for infection of patients with type-2 diabetes mellitus. Exp Ther Med. 2019;18(1):722-728. doi:10.3892/etm.2019.7611
10. Abrahamson M, Olafsson I, Palsdottir A, et al. Structure and expression of the human cystatin C gene. Biochem J. 1990;268:287–94.
11. Turk V, Stoka V, Turk D. Cystatins: biochemical and structural properties, and medical relevance. Front Biosci. 2008;13:5406–20.
12. Zhang J, Wang P, Huang YB, et al. Plasma cathepsin L and its related pro/antiangiogenic factors play useful roles in predicting rich coronary collaterals in patients with coronary heart disease. J Int Med Res. 2010;38:1389–403.
13. Turk V, Stoka V, Turk D. Cystatins: biochemical and structural properties, and medical relevance. Front Biosci. 2008;13:5406–20
14. Cheng-Cheng Ma, Chun-Cui Duan, Rong-Cai Huang, and Hai-Qin Tang Association of circulating cystatin C levels with type 2 diabetes
mellitus: a systematic review and meta-analysis 2020; 16(3): 648–656.
15. Lee BW, Ihm SH, Choi MG, Yoo HJ. The comparison of cystatin C and creatinine as an accurate serum marker in the prediction of type 2 diabetic nephropathy. Diabetes Res Clin Pr. 2007;78(3):428–34.
16. Rule AD, Bergstralh EJ, Slezak JM, Bergert J, Larson TS. Glomerular fltration rate estimated by cystatin C among diferent clinical presentation. Kidney Int. 2006;69(2):399–405
17. K. Sahakyan, K. E. Lee, A. Shankar, and R. Klein, “Serum cystatin C and the incidence of type 2 diabetes mellitus,” Diabetologia, vol. 54, no. 6, pp. 1335–1340, 2011.
18. Ma CC, Duan CC, Huang RC, Tang HQ. Association of circulating cystatin C levels with type 2 diabetes mellitus: a systematic review and meta-analysis. Arch Med Sci. 2019 Mar 11;16(3):648-656. doi: 10.5114/aoms.2019.83511. PMID: 32399114; PMCID: PMC7212213.
19. Akbari M, Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology. 2018 Jun;26(3):685-698. doi: 10.1007/s10787-018-0458-0. Epub 2018 Mar 5. PMID: 29508109.
20. Fukunaga S, Hoshino Y, Sonoda H, Kawanishi M, Yamauchi A, Kato S, Yoshikane K, Shiina H, Tanabe K, Ito T. A Remarkable Elevation in the Procalcitonin Levels Due to Diabetic Ketoacidosis in a Hemodialysis Patient. Intern Med. 2021 Apr 15;60(8):1231-1235. doi: 10.2169/internalmedicine.5841-20. Epub 2020 Nov 23. PMID: 33229806; PMCID: PMC8112968.